Skip to content
naulon
Not checkedNot checked for notices yet.

Biphenotypic siononasal sarcoma with acute exacerbation: A case report

Hiroshi Okuda, Bunya Kuze, Hirofumi Shibata and 7 more

Otolaryngology Case Reports · 2020

doi:10.1016/j.xocr.2020.100190 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background: Biphenotypic sinonasal sarcoma (BSNS) is a rare sarcoma with neural and myogenic pathological features. Histopathologically, BSNS has been regarded as a low-malignant tumor with favorable prognosis. Herein, we report a case of BSNS with a seemingly high-grade malignancy and an extremely acute exacerbation. Case description: A 64-year-old woman was diagnosed with BSNS and underwent surgical extraction of a tumor twice. Two months later after the second operation, recurrence occurred, with intracranial tumor extension as well as infiltrations around the carotid artery. Two cycles of chemotherapy with doxorubicin and ifosfamide were administered, which significantly reduced the tumor volume. Subsequently, a treatment with oral pazopanib was administered. No tumor progression was observed in the next 2 and a half months, followed by local progression. Discussion: Our case seems to be entirely different from those described in previous reports on BSNS and should be regarded clinically as an extremely high malignant tumor. This high malignancy involved the high proliferative activity and invasiveness of critical organs such as in the intracranial area. AI therapy consisted of a regimen with doxorubicin and ifosfamide showed anti-tumor effects, as well as a temporary inhibition of tumor progression was achieved with pazopanib. Conclusion: AI therapy and pazopanib might be considered as a potential postoperative adjuvant therapy and second-line therapy for severe BSNS.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.